• linkedin
  • Increase Font
  • Sharebar

    PCa-specific mortality not affected by comorbidity

    Increased comorbidity does not raise death risk regardless of radical treatment type

    Comorbidity does not affect prostate cancer-specific mortality, according to authors of a large prospective observational study of men in Sweden, published in the Journal of Clinical Oncology (2017; 35:3566-74).

    “Regardless of radical treatment type [radical prostatectomy or radical radiotherapy], increased comorbidity does not seem to significantly affect the risk of dying from prostate cancer,” reported lead study author Prabhaker Rajan, MD, PhD, consultant urologist at Barts Health and University College London Hospitals NHS Trust and clinical senior lecturer in urology at Queen Mary University of London, and colleagues. “Consequently, differences in oncologic outcome that were observed in population-based comparative effectiveness studies of prostate cancer treatments do not seem to be a result of the varying distribution of comorbidity among treatment groups.”

    Also see: Is favorable-risk GG2 prostate Ca suitable for active surveillance?

    Comorbidities and their impacts on life expectancy can importantly influence prostate cancer treatment decision-making. Survival benefits for radical prostatectomy and radical radiotherapy emerge after a decade more, so guidelines recommend that these treatments not be undertaken in men with life expectancy of 10 years or less, the authors noted. Previous studies have yielded mixed outcomes for the effect of comorbidity on prostate cancer-specific mortality.

    The authors sought to use a population-based observational national study of 118,543 men diagnosed with prostate cancer between 1998 and 2012, using data from nine national registries representing more than 98% of men diagnosed with prostate cancer in Sweden after 1998. Multivariate analyses were conducted using patient marital status and educational attainment, tumor characteristics (including serum PSA, tumor grade, and clinical stage), and treatment type. Patient data were stratified using the four-category Charlson comorbidity index: 0, 1, 2, or ≥3.

    “After adjustments for patient and tumor characteristics, the effect of comorbidity on prostate cancer-specific mortality was lost but maintained for other-cause mortality,” the authors reported.

    Next: Watchful waiting, ADT groups analyzed


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available